By Matthew Harrington, Global Head, Clinical Product, Syneos Health | Artificial intelligence (AI) now features prominently in boardroom and executive discussions across the life sciences industry.
Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
10d
Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes
Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 programMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex ...
Basket Trials Evaluating Tazemetostat Combinations for Multiple New Heme and Solid Tumor Cancers to be Initiated in Second Half 2021 “The recent accelerated approvals of TAZVERIK in Epithelioid ...
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry TORONTO ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains ...
Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results